ArticleEClinicalMedicine2019
Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors.
Article in EClinicalMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Identification of risk factors for attempted suicide by self-poisoning and a nomogram to predict self-poisoning suicide.Frontiers in public health · 2023Trial
- Nuclear grading of myxoid liposarcoma robustly predicts patient outcome: a study of 280 patients.Virchows Archiv : an international journal of pathology · 2026Article
- Article
- Prognostic Factors and Outcomes for Post-Radiation Sarcoma-A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Pooled Analysis of Trabectedin Efficacy in Myxoid/Round Cell Liposarcoma from Three Prospective Clinical Trials.Cancers · 2026Article
- Early recurrence and prognosis in patients undergoing resection of primary retroperitoneal sarcoma: an international, retrospective cohort study.EClinicalMedicine · 2026Article
- Organizing Care Matters: Fragmented Pathways Double Early Local Recurrence Risk in Sarcoma.Cancers · 2026Article
- Prediction hospital mortality for critical illness lung cancer patients with pneumonia.BMC infectious diseases · 2026Article
- Evaluation of magnetic resonance imaging parameters and compliance with guidelines in soft tissue sarcomas.BMC cancer · 2026Article
- Applying Radiomics to Predict Outcomes in Patients with High-Grade Retroperitoneal Sarcoma Treated with Preoperative Radiotherapy.Journal of imaging · 2025Article
- Dynamic nomogram for predicting long-term survival in patients with brain abscess.Chinese neurosurgical journal · 2025Article
- Predicting progression-free survival in sarcoma using MRI-based automatic segmentation models and radiomics nomograms: a preliminary multicenter study.Skeletal radiology · 2025Article
- [Localized soft tissue sarcomas].Chirurgie (Heidelberg, Germany) · 2025Review
- De Novo Natural Language Processing Algorithm Accurately Identifies Myxofibrosarcoma From Pathology Reports.Clinical orthopaedics and related research · 2025Article
- Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?Clinical orthopaedics and related research · 2024Article
- Dynamic Prediction of Overall Survival for Patients with Osteosarcoma: A Retrospective Analysis of the EURAMOS-1 Clinical Trial Data.Current oncology (Toronto, Ont.) · 2024Article
- CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma - a short report.Cancer drug resistance (Alhambra, Calif.) · 2024Article
- Outcome and survival analysis of pulmonary metastasectomy for primary sarcoma with pulmonary metastases.Frontiers in surgery · 2024Article
- Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas.iScience · 2023Article
- Staging Systems and Nomograms for Soft Tissue Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrognostic nomograms for patients with extremity soft tissue sarcoma (eSTS) typically predict survival or the occurrence of local recurrence or distant metastasis at time of surgery. Our aim was to develop and externally validate a dynamic prognostic nomogram for overall survival in eSTS survivors for use during follow-up.
methodsAll primary eSTS patients operated with curative intent between 1994 and 2013 at three European and one Canadian sarcoma centers formed the development cohort. Patients with Fédération Française des Centres de Lutte Contre le Cancer (FNCLCC) grade II and grade III eSTS operated between 2000 and 2016 at seven other European reference centers formed the external validation cohort. We used a landmark analysis approach and a multivariable Cox model to create a dynamic nomogram; the prediction window was fixed at five years. A backward procedure based on the Akaike Information Criterion was adopted for variable selection. We tested the nomogram performance in terms of calibration and discrimination.
findingsThe development and validation cohorts included 3740 and 893 patients, respectively. The variables selected applying the backward procedure were patient's age, tumor size and its interaction with landmark time, tumor FNCLCC grade and its interaction with landmark time, histology, and both local recurrence and distant metastasis (as first event) indicator variables. The nomogram showed good calibration and discrimination. Harrell C indexes at different landmark times were between 0.776 (0.761-0.790) and 0.845 (0.823-0.862) in the development series and between 0.675 (0.643-0.704) and 0.810 (0.775-0.844) in the validation series.
interpretationA new dynamic nomogram is available to predict 5-year overall survival at different times during the first three years of follow-up in patients operated for primary eSTS. This nomogram allows physicians to update the individual survival prediction during follow-up on the basis of baseline variables, time elapsed from surgery and first-event history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.